Cart
sales@molnova.com
SB1317 hydrochloride
CAS No.
SB1317 hydrochloride ( TG-02 hydrochloride )
Catalog No. M19398 CAS No.
SB1317 is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 70 | Get Quote |
|
| 5MG | 125 | Get Quote |
|
| 10MG | 206 | Get Quote |
|
| 25MG | 370 | Get Quote |
|
| 50MG | 451 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSB1317 hydrochloride
-
NoteResearch use only not for human use.
-
Brief DescriptionSB1317 is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
-
DescriptionSB1317 is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
-
SynonymsTG-02 hydrochloride
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2; FLT3; JAK2
-
Research AreaCancer
-
IndicationAnaplastic astrocytoma; Glioblastoma
Chemical Information
-
CAS Number--
-
Formula Weight408.92
-
Molecular FormulaC23H25ClN4O
-
Purity>98% (HPLC)
-
SolubilityDMSO:26.5 mg/mL
-
SMILESCl.CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.William AD et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-571426-tetraazatetracyclo[19.3.1.1(26).1(812)]heptacosa-1(25)2(26)358(27)911162123-decaene (SB1317/TG02) a potent inhibitor of cyclin dependent kina.
molnova catalog
related products
-
CCT-251921
A potent, selective, and orally bioavailable inhibitor of CDK8 and CDK19 with IC50of 2.3 nM and 2.6 nM respectively.
-
AZD-4573
AZD-4573 (AZD4573) is a potent and selective inhibitor of CDK9, with fast-off binding kinetics and high selectivity versus other kinases, including other CDK family kinases.
-
CDK7 and 9 inhibitor...
A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.
